Ixico announces extensions to two studies

Data analytics company Ixico announced a £1.8m extension to a phase 3 study in Huntington's Disease on Monday, which it had previously announced in September 2018.

The AIM-traded firm also confirmed a £0.6m extension to a study programme in Progressive Supranuclear Palsy, which was initially announced in October.

“Huntington’s Disease and Progressive Supranuclear Palsy are devastating neurological conditions, currently with no cure, and we are pleased to build momentum in our mission to support our clients in delivering data analytics in these challenging areas of rare, neurodegenerative disease,” said chief executive officer Giulio Cerroni.

“Our services will enable them to measure the impact of the trialled drugs with greater confidence and potentially unlock new insights into disease progression.

“Following the recent announcement of our strong trading results for the 2019 financial year, the expansion of these work programmes for two large pharma clients is further evidence of the value that we deliver through our proprietary AI data analytics and our ability to scale our operations to meet increasing size and complexity of clinical trials as they progress through clinical development.”

At 1453 GMT, shares in Ixico were up 13.84% at 80.26p.